Study Objective: To examine the prevalence of circadian misalignment in clinically diagnosed delayed sleep phase disorder (DSPD) and to compare mood and daytime functioning in those with and without a circadian basis for the disorder. Methods: One hundred and eighty-two DSPD patients aged 16-64 years, engaged in regular employment or school, underwent sleep-wake monitoring in the home, followed by a sleep laboratory visit for assessment of salivary dim light melatonin onset (DLMO). Based on the DLMO assessments, patients were classified into two groups: circadian DSPD, defined as DLMO occurring at or after desired bedtime (DBT), or non-circadian DSPD, defined as DLMO occurring before DBT. Results: One hundred and three patients (57%) were classified as circadian DSPD and 79 (43%) as non-circadian DSPD. DLMO occurred 1.66 hours later in circadian DSPD compared to non-circadian DSPD (p < .001). Moderate-severe depressive symptoms (Beck Depression Inventory-II) were more prevalent in circadian DSPD (14.0%) than in non-circadian DSPD (3.8%; p < .05). Relative to non-circadian DSPD patients, circadian DSPD patients had 4.31 times increased odds of at least mild depressive symptoms (95% CI 1.75 to 10.64; p < .01). No group differences were found for daytime sleepiness or function, but DSPD symptoms were rated by clinicians to be more severe in those with circadian DSPD. Conclusions: Almost half of patients clinically diagnosed with DSPD did not show misalignment between the circadian pacemaker and the DBT, suggesting that the reported difficulties initiating sleep at the DBT are unlikely to be explained by the (mis)timing of the circadian rhythm of sleep propensity. Circadian misalignment in DSPD is associated with increased depressive symptoms and DSPD symptom severity.
INTRODUCTION
Delayed sleep phase disorder (DSPD) is a circadian rhythm sleep disorder (CRSD) characterized by a delay in the major sleep episode relative to the desired or required sleep-wake cycle, resulting in difficulty both initiating sleep and subsequently awakening at the desired or required clock times. 1 DSPD is more prevalent in teenagers and young adults (7-16%) 1 than in middle-aged adults (3.1%). 2 DSPD is associated with significant functional impairments. Adult DSPD patients report significant impairments to job performance, financial difficulties, and marital problems, 3 and also greater medication use, particularly hypnotics. 4 Adolescents with DSPD show poorer school performance, 5, 6 dysfunctional school behaviors, underachievement, 7 and are more likely to engage in negative health behaviors such as smoking, 8 and excessive alcohol 6 and caffeine use. 9 Depressive symptoms are commonly reported in DSPD patients. 10 Abe and colleagues showed that 64% of patients with DSPD had a comorbid diagnosis of depression. 11 In a survey of 917 consecutive sleep clinic patients, 41% of DSPD patients showed evidence of depressive symptoms. 12 Preliminary findings suggest that treatment of DSPD with exogenous melatonin significantly improved depressive symptoms. 13 The higher rate of depression in the DSPD population is perhaps not surprising, as circadian misalignment appears to play a role in the pathophysiology of mood disorders, 14 particularly depression, 15, 16 although the precise mechanisms underlying the associations are unclear. Disruption of the circadian system increases vulnerability to major depression, 17, 18 and specific polymorphisms in the core circadian clock genes CLOCK, BMAL1, PERIOD3, and TIMELESS are associated with increased risk of mood disorders. 19 Furthermore, short sleep duration, which is common in DSPD patients, may interact with a vulnerability generated by a polymorphism in the serotonin transporter gene (5-HTTLPR in SLC6A4) to increase the risk of depression in DSPD. 20 
Statement of Significance
Delayed sleep phase disorder (DSPD) is a highly prevalent, often undiagnosed primary circadian sleep disorder, caused by a delay in the endogenous circadian clock. Here we demonstrated that almost 50% of patients clinically diagnosed with DSPD did not show evidence of having a delay in circadian clock relative to desired bedtime, suggesting a non-circadian etiology for their sleep complaints. Additionally, we found that those with circadian misalignment showed significantly elevated depressive symptoms, providing further evidence for a circadian basis for mood disturbances. These findings support the measurement of the melatonin rhythm to distinguish patients with and without circadian misalignment, as a part of the routine diagnostic process. Furthermore, measurement of the melatonin rhythm may improve treatment outcomes by more accurately phenotyping patients to identify those who are likely to benefit from chronobiological treatments and to optimize the timing of chronobiological treatments such as light-dark exposure and melatonin.
In clinical practice, DSPD as a circadian disorder is often not easily differentiated from sleep initiation insomnia, particularly in the absence of an objective and reliable diagnostic test for DSPD. Therefore, some patients classified as having DSPD based on current diagnostic criteria, which rely predominantly on self-reported symptoms, 21, 22 may not show a delay in the timing of the circadian pacemaker [23] [24] [25] [26] and be incorrectly diagnosed. Separate from the circadian mechanisms that underlie DSPD, DSPD-like symptoms may be attributed to reduced homeostatic sleep pressure leading to increased evening alertness, 27 poor sleep hygiene, 28 and pre-sleep hyperarousal. 29, 30 Different treatment approaches are likely needed to effectively manage DSPD symptoms depending on the specific etiology.
We investigated the timing of the melatonin rhythm relative to desired sleep time in patients with clinically diagnosed DSPD 1 to determine the proportion of DSPD attributable to circadian misalignment. Patients were classified into circadian and non-circadian DSPD types based on a laboratory-based circadian phase assessment using salivary dim light melatonin onset (DLMO). We then compared mood and daytime functioning in those with and without delayed circadian timing. Figure 1 and Supplementary Material for detailed inclusion/exclusion criteria.
METHOD

Circadian and Non-Circadian DSPD Phenotypes
Participants were classified into phenotype groups based on the relationship between DLMO and desired bedtime (DBT). A circadian DSPD phenotype was defined as having a DLMO time at or after DBT. To allow for potential measurement error in DLMO and/or DBT, those with DLMO occurring up to 30 minutes before DBT were also classified as circadian DSPD. The non-circadian DSPD phenotype was defined as having a DLMO time greater than 30 minutes before DBT. DBT was derived from the following question: "On the night before school or work, what time would you need to go to bed in order to feel fully rested in the morning?" 31 Given that the diagnostic criteria for DSPD refer to required or DBT (Criterion A), 32 our definition of circadian DSPD phenotype was based on the timing of the onset of melatonin synthesis relative to desired or required bedtime, rather than actual bedtime, which may be driven by social demands or constraints. In healthy individuals, melatonin onset occurs on average ~2 hours before sleep onset. 33 In our patient population, we first determined whether or not DBT differed from habitual bedtime. If it did, we then examined whether or not DLMO was appropriately timed relative to desired sleep time. We assumed that if DBT occurred at least 30 minutes after DLMO, the timing of DLMO (and, by extrapolation, the circadian rhythm of sleep propensity) was unlikely to be the primary cause of the reported difficulty initiating sleep at the DBT (ie, the hallmark symptom of DSPD).
Screening
Participants completed online questionnaires assessing DSPD symptoms, 31 sleep-wake habits, sleep impairments, daytime functioning, and diurnal preference 34 (see Supplementary Material for details); further screening by telephone; formal screening visit after providing written informed consent; and a clinical consultation with a physician specializing in sleep medicine. In addition to confirming diagnosis of DSPD, 1 the physician rated symptom severity and duration using the Clinical Global Impressions of Severity (CGI-S) 35 (see Supplementary Material).
Sleep-Wake Assessment
Participants were asked to maintain their usual sleep-wake patterns and were monitored for at least 7 days immediately prior to a laboratory visit using a sleep diary, verified by wrist actigraphy (Actiwatch Spectrum, Philips Respironics, Bend, OR). In cases of actigraphy malfunction or non-compliance (n = 13; 7.03%), participants were required to repeat the sleep-wake monitoring. Participants also completed a daytime activity diary to record daytime work, school, or study commitments. The Morningness-Eveningness Questionnaire was used to determine diurnal preference based on established cut-off scores for these categories. 34 To increase probability of DSPD, at preliminary screening, those with a composite score greater than 49, indicating that they were either intermediate or morning types, were excluded from the study. Mean self-reported habitual bedtime, habitual sleep time, and total sleep time were calculated from sleep diaries over 7 consecutive days.
Daytime Sleepiness and Functioning
Prior to the laboratory visit, participants completed an online questionnaire including the following: Epworth Sleepiness Scale (ESS), 36 Sheehan Disability Scale (SDS), 37 and Beck Depression Inventory, Second Edition (BDI-II) 38 (see Supplementary Material). The ESS was collapsed into two categorical variables based on the recommended reference range of 0-10 (normal) and greater than 10 (excessive daytime sleepiness).
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Circadian Phase Assessment
After the sleep-wake assessment, participants attended the laboratory for measurement of circadian phase. Participants arrived 6 hours before their self-reported habitual sleep onset time and remained in a light-proof, sound-attenuated, and temperature-controlled suite until at least 2 hours after their habitual sleep onset time. Ambient light levels were maintained at less than 10 lux (measured in the direction of gaze at standard height of seated position; vertical plane, 137 cm from floor [40] [41] [42] ) and saliva samples (~2 mL) were collected hourly from 5 hours before to 2 hours after habitual sleep onset time. Participants were instructed to remain seated for 20 minutes and were not permitted to consume food or beverages for 10 minutes before each sample. They were permitted to watch television (<10 lux), read, and engage in quiet activities between samples but were required to remain awake for the duration of the visit, monitored by direct observation. Samples were collected (Salivette, Sarstedt, Numbrecht, Germany) as previously described, 43 centrifuged, and stored immediately at −20°C. After the final sample collection, participants were transported to their homes.
Dim Light Melatonin Onset
Saliva (200 μL) was assayed in duplicate for melatonin by radioimmunoassay 44 within 1 week of collection, using procedures developed by University of Adelaide and licensed to Buhlmann Laboratories (Allschwil, Switzerland). Limit of detection of the assay was 1 pg/mL and the interassay coefficients of variability (CVs) were 7.4% at 4.41 pg/mL and 10.7% at 48.14 pg/mL. DLMO for each participant was determined as the time that melatonin concentrations crossed and remained above a threshold of 2.3 pg/mL, calculated from linear interpolation between the samples immediately before and after the threshold. 45 Data Analysis SPSS Statistics Version 20.0 (IBM, Armonk, NY) was used for all data analysis. Data are expressed as mean ± SD unless otherwise stated. Significance level was .05. Mood, as assessed by BDI-II, was defined as the primary outcome. BDI-II scores were categorized as follows: minimal depression (0-13); mild (14) (15) (16) (17) (18) (19) ; and moderate-severe . 38 Variables were compared between circadian and non-circadian DSPD phenotypes using chi-squared (goodness of fit) test or independent samples t test.
A direct logistic regression was conducted to assess the association between DSPD phenotypes and depression symptom severity (minimal vs. mild-severe depression symptoms). Age, sex, total sleep time, and habitual sleep time were included as potential confounders in the model. DSPD, 79 participants (43%) did not show an abnormal phase relationship between DLMO time and DBT and were thus classified as non-circadian DSPD phenotype. The remaining 103 participants (57%) were classified as circadian DSPD phenotype. No significant differences were found between DSPD phenotype groups in age, BMI, sex, or nature of work or study commitments, although we observed a trend for circadian DSPD phenotype to be younger (see Table 1 ).
RESULTS
Participant Characteristics
Circadian and non-circadian DSPD phenotypes did not show differences in desired or habitual bedtimes on nights before work and non-work days, and wake times on work days (see Table 2 ). Wake time on non-work days, however, was significantly later in the circadian DSPD group compared to the non-circadian DSPD group (mean difference 0.80 hours; 95% CI 0.30 to 1.30; p < .01). Circadian and non-circadian DSPD phenotypes did not show differences in diurnal preference ( (Figure 2A 
Depressive Symptoms
Overall, 24.2% of the sample showed mild-severe depression symptoms (BDI-II score ≥ 14) and 9.6% showed moderate-severe depression symptoms (BDI-II score ≥ 20). Of those reporting mild-severe depression symptoms, 81% had a circadian DSPD phenotype ( Figure 2B ). Mean BDI-II score was higher in the circadian DSPD phenotype (10.55 ± 10.20) than in the noncircadian phenotype (7.24 ± 6.02) (p < .01). A significantly greater proportion of participants in the circadian DSPD group reported mild-severe depression symptoms (35.0%) compared with the non-circadian DSPD participants (10.3%; p < .001; Figure 3 ). Likewise, a significantly greater proportion of participants in the circadian DSPD group reported moderate-severe depression symptoms (14.0%) compared with the non-circadian DSPD participants (3.8%; p < .05). In post hoc analyses, we excluded 11 participants who reported current antidepressant medication use (6.0% of sample) and found that depressive symptoms remained significantly higher in those with a circadian DSPD phenotype (10.44 ± 10.36; n = 95) compared to those with the non-circadian phenotype (7.17 ± 5.01; n = 76; p < .05).
We assessed the association between DSPD phenotype and depression symptoms (minimal depressive symptoms vs. To further examine the relationship between circadian misalignment and depression, we compared the phase difference between DLMO and DBT in those with mild-severe depressive symptoms to those with minimal depressive symptoms. In those with mild-severe depressive symptoms, DLMO occurred 0.49 ± 1.30 hours after DBT (range: DLMO 2.80 hours before to 3.13 hours after DBT), whereas DLMO occurred 0.51 ± 1.31 hours before DBT (DLMO; range: DLMO 3.43 before to 3.22 hours after DBT) in those with minimal depressive symptoms (95% CI 1.45 to −0.56; p < .001).
Sleepiness and Daytime Function
There were no significant group differences in the questionnaire-based assessments for sleepiness (χ 2 (1) = 0.393; p = .531), or daytime functioning (t(177) = 0.704; p = .482; Table 2 ).
Clinical Severity Assessment
On the clinician-rated CGI-S, completed before the assessment of circadian phase, more participants in the circadian DSPD phenotype group were classified as moderately-severely ill (n = 63; 61.2%) compared with the non-circadian phenotype group (n = 33; 42.9%; χ 2 (1) = 5.934; p < .05; Table 2 ). 
DISCUSSION
This study examined the phase of the circadian melatonin rhythm relative to the desired sleep-wake cycle in a sample of DSPD patients and compared mood and daytime function in patients with and without a circadian phase misalignment. There are two key findings. First, we showed that almost half (43%) of patients with a clinical diagnosis of DSPD did not have misaligned timing of the melatonin rhythm and were therefore misdiagnosed with a CRSD. Second, those with misaligned timing of the melatonin rhythm relative to the desired sleep-wake cycle reported a higher prevalence and severity of depressive symptoms than those who did not have misaligned rhythms. Clinician assessments, made prior to circadian phase assessment, showed that a higher proportion of the patients who have misaligned timing of the melatonin rhythm have moderate-severe illness severity compared with those without circadian misalignment. These findings demonstrate that in patients with DSPD symptoms, those who have objectively assessed circadian misalignment report greater depressive symptoms and illness severity. To our knowledge, this is the first study to examine circadian phase relative to DBT in a clinically diagnosed DSPD sample, showing that a high proportion of patients are misdiagnosed with a CRSD. Interestingly, despite its recognized circadian etiology, current diagnostic criteria do not include assessment of circadian phase, using markers such as DLMO. 32, 46 In the current study, 43% of patients who were clinically diagnosed with DSPD were found to have no evidence of circadian misalignment (ie, DLMO occurred at 30 minutes or more before DBT). This finding supports the contention 22, 47, 48 that circadian phase assessment should become part of the standard diagnostic evaluation for DSPD to better differentiate phenotypes and optimize the treatment regimen based on the underlying etiology. Cost-effectiveness and reimbursement options for DLMO as a diagnostic tool remain to be evaluated.
One reason for determining the objective presence of circadian misalignment is that individual DLMO information may have implications for therapy. While those with circadian misalignment may benefit from treatments that specifically target the circadian system, such as light-dark exposure and/or melatonin (agonist) therapy, [49] [50] [51] [52] as well as other treatments such as cognitive behavioral therapy for insomnia, 53 those without circadian misalignment are not likely to benefit from the targeted circadian interventions. Therefore, DLMO assessment may provide information that enables a more targeted therapeutic approach to patients with symptoms of DSPD.
Based on subjective sleep-wake assessments, which form the basis of current diagnostic criteria for the disorder, those with and without circadian misalignment were relatively indistinguishable. This is unsurprising, given that there can be considerable interindividual variability in phase relationships between the melatonin rhythm and the sleep-wake cycle, despite similar sleep-wake schedules. 33, 43, 54, 55 There is also substantial intraindividual variability observed in the current study, as evidenced by the difference in phase relationships between the melatonin rhythm and habitual bedtime on work and non-work nights. Habitual bedtime and wake time and DBT were not significantly different between groups on work nights, but habitual wake time on non-work days was significantly later in the circadian DSPD phenotype group compared to the non-circadian DSPD group, consistent with the significantly later timing of the melatonin rhythm in this group.
Previous studies have reported associations between circadian rhythm misalignment and depressed mood. 56, 57 In seasonal depression, depressive symptom severity is strongly related to the degree of circadian rhythm misalignment. 58 High rates of depression have also been reported in DSPD patients. 10, 11 A previous study (n = 20) showed abnormal timing of the urinary melatonin metabolite rhythm in DSPD patients with depressive symptoms compared to those without depressive symptoms. 13 Our study shows that circadian misalignment in patients clinically diagnosed with DSPD is strongly associated with depressive symptoms, even after controlling for total sleep time and other potential confounding variables; those in the circadian DSPD group had 4.31 times increased odds of reporting at least mild depressive symptoms. The relationship between circadian misalignment and depressive symptoms was further supported by the finding that in those with at least mild depressive symptoms, DLMO occurred 0.5 hours after DBT, while DLMO occurred 0.5 hours before DBT in those with minimal depressive symptoms.
While the exact mechanisms linking circadian misalignment and mood disturbances are not yet fully understood, there is evidence that the genes associated with circadian misalignment may contribute to susceptibility to mood disorders. 19 Polymorphisms of circadian clock genes such as CLOCK, PER2, and PER3 are reported to be associated with extreme evening preference [59] [60] [61] [62] ; although not all studies agree. [63] [64] [65] [66] Some of these genes are also associated with an increased susceptibility to mood disorders, 67, 68 providing a possible genetic basis for the observed associations. In our study, DLMO occurred almost 2 hours later in the circadian DSPD phenotype group in conjunction with higher depressive symptoms. The circadian DSPD phenotype on average wakes up closer to the time of the nadir of the body temperature rhythm, which is also the nadir of positive affect. 69 Frequent experience of low positive affect in the mornings may contribute to the increased depressive symptoms of the circadian DSPD group.
Chronic sleep deficiency and delayed sleep timing 70, 71 are both associated with increased risk of depression and are commonly experienced by DSPD patients. 72 In our analysis, however, by including both the duration and timing of sleep as potential confounders, we showed that misaligned timing of the melatonin rhythm relative to the desired sleep-wake cycle is independently associated with depressive symptoms. Finally, a missense variant (P10L) of the melanopsin gene is associated with predisposition to seasonal depression, 73 indicating that alteration in circadian light sensitivity may contribute to mood disturbances.
In those individuals diagnosed with DSPD but found to have no circadian misalignment, factors that may contribute to the DSPD-like sleep complaints include decreased rate of accumulation of homeostatic sleep pressure 27 and psychophysiological factors that increase pre-sleep arousal, such as anxiety. 29 Hiller and colleagues 30 recently reported that sleep initiation in adolescents is impeded by cognitive processes such as catastrophizing as well as anxiety, although their study did not measure circadian phase. While our study did not include participants with a current diagnosis of an anxiety disorder, because we did not specifically screen for such disorders, it is possible that those with undiagnosed anxiety disorders were included. These factors could help explain why sleep initiation is difficult in the non-circadian DSPD phenotype, despite having a normal circadian phase.
No group differences were observed for self-reported measures of daytime sleepiness or functional impairments. Notably, however, DSPD patients in both groups reported a relatively high level of absenteeism and lost productivity, consistent with our previous report, 31 and other studies reporting poorer work/ academic outcomes associated with DSPD. 1, 3 We found that, on average, patients reported 1.5 days of missed work or school and 1.1 days of lost productivity in the past week, translating annually to approximately 75 and 55 days of lost work and lost productivity, respectively. Notwithstanding the likely selection bias in our study, the absenteeism rate is markedly higher than the rate observed in the general population, which is reported to be 4.4 days per year in the United Kingdom 74 and 8.9 days per year in Australia. 75 Limitations of the study are noted. Healthy volunteers were not included as a comparison group, because the primary aim was to assess melatonin rhythm phase and compare clinical characteristics of DSPD patients with and without circadian misalignment. Although we used validated questionnaires for assessing depressive symptoms and daytime function, we did not include diagnostic interviews or objective functional assessments.
The current findings have implications for both diagnosis and treatment of DSPD. Current diagnostic criteria rely almost exclusively on self-reported symptoms, which do not reliably distinguish patients with and without an underlying circadian basis for their disorder. We show that assessment of circadian phase would greatly improve the diagnosis of DSPD. Better clinical assessments will also allow better selection and timing of treatment, potentially leading to improved outcomes. Our finding that DSPD illness severity and depression symptoms are elevated in DSPD patients with circadian misalignment highlights the importance of circadian phase assessment in the diagnosis and optimal management of DSPD and the potential contribution of disturbances of the circadian system to mood disorders.
